Disease relevance of Epodyl

• The ultrastructure of transitional cell carcinomas of the human urinary bladder treated with ethoglucid or mitomycin [1].
• Intravesical epodyl in the management of bladder tumors: combined experience of the Yorkshire Urological Cancer Research Group [2].
• Severe chemocystitis occurred in some patients who received ethoglucid (three had to discontinue treatment), while no local toxicity was seen with IFN-alpha 2b treatment [3].
• Epodyl has a place in the treatment of vesical papillomas when other methods have failed [4].
• Irritative cystitis occurred in 16 per cent of the series, and in these cases Epodyl treatment had to be stopped [4].

High impact information on Epodyl

• Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone [5].
• Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of a European organization for research on treatment of cancer. Randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone [6].
• Epodyl was instilled into the pelvis and ureter through a ureteric catheter [7].
• Tween 80 was shown to enhance significantly the cytotoxic activities of the four drugs (adriamycin, epodyl, mitomycin-c, thiotepa) most frequently administered intravesically to treat superficial bladder cancer [8].
• Widespread, well differentiated (grade I) bladder tumours confined to the mucosa (stage Ta) were treated with regular intravesical instillations of ethoglucid (Epodyl) in 24 patients [9].

Chemical compound and disease context of Epodyl

• Patients with superficial transitional cell carcinoma of the bladder were entered in a randomized clinical trial to compare the efficacies of transurethral resection alone or followed by bladder instillation of doxorubicin hydrochloride or ethoglucid (Epodyl) for 1 year [6].

Associations of Epodyl with other chemical compounds

• Human bladder tumor cell implantation was prevented following exposure of the cells to distilled water, epodyl or mitomycin C, and significantly reduced following one hour incubation in cisplatinum and doxorubicin [10].

Analytical, diagnostic and therapeutic context of Epodyl

• Electron microscopy studies of the ultrastructure of bladder carcinoma treated by intravesical instillation of ethoglucid and mitomycin are described [1].
• CONCLUSIONS: In regard to time to first recurrence and recurrence rate per year this study indicates that adjuvant chemotherapy with doxorubicin and ethoglucid using the indicated schedule is superior to transurethral resection alone [5].
• Epodyl is used best as an adjunct to transurethral resection or diathermy of T1 bladder lesions [2].
• All patients had a history of recurrent multiple noninvasive superficial transitional cell carcinoma of the bladder, and were previously unsuccessfully treated with intravesical chemotherapy (epodyl and/or adriamycin) [11].

References